JP Morgan Chase’s Enveric Biosciences ENVB Stock Holding History

JP Morgan Chase’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	-$4K	–	6557
2022 Q1	$4K	Buy	+1	New	+$4.42K	﹤0.01%	6345

Other funds holding ENVB

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase's ENVB Position: Q2 2022 in Review

JP Morgan Chase sold out of Enveric Biosciences (ENVB) in Q2 2022, closing a stake of 1 share — an estimated $4K sold.

JP Morgan Chase first reported a position in ENVB in Q1 2022 and held it in 1 quarter. The position peaked at $4K in Q1 2022. 21 funds tracked by Wall St. Rank hold ENVB as of Q2 2022.

JP Morgan Chase reported no remaining Enveric Biosciences position as of Q2 2022 after selling out during the quarter.
JP Morgan Chase sold 1 Enveric Biosciences share in Q2 2022, an estimated $4K.
JP Morgan Chase first reported a position in Enveric Biosciences in Q1 2022 and held it in 1 quarter.
JP Morgan Chase's Enveric Biosciences position peaked at $4K in Q1 2022.
21 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2022.

Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.